Based on their training set of 42 patients, they identified eight potential biomarkers for the diagnosis of acute GVHD, and additional studies in 424 patients demonstrated that the four mediators CXCL8, IL2 receptor α (IL2Rα), TNFR1 and HGF, optimally discriminated patients with and without acute GVHD. This evidence concerns the gene TNFRSF1A and acute graft versus host disease.